Ironwood Pharmaceuticals, Inc.

As of June 30, 2026, Ironwood Pharmaceuticals, Inc. Class A carries a market capitalization of 611.39M, placing it among publicly traded companies globally. Its enterprise value stands at 889.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ironwood Pharmaceuticals, Inc. Class A's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Ironwood Pharmaceuticals, Inc. Class A has 165.24M shares outstanding.

As of June 30, 2026, Ironwood Pharmaceuticals, Inc. Class A trades at a trailing price-to-earnings ratio of 5.31. The price-to-sales ratio is 1.77, and the price-to-book ratio stands at -4.32.

As of June 30, 2026, Ironwood Pharmaceuticals, Inc. Class A trades at an EV/EBITDA multiple of 4.31 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.61 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 4.34 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Ironwood Pharmaceuticals, Inc. Class A trades at an EV/FCF ratio of 4.94, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 889.50M versus a market cap of 611.39M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Ironwood Pharmaceuticals, Inc. Class A maintains a current ratio of 6.06, meaning it holds 6.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -245.22, indicating conservative leverage, while an interest coverage ratio of 7.26 demonstrates adequate ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on invested capital (ROIC) comes in at 55.28 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 41.35, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 57.17, useful for judging operating efficiency across full business cycles. The company generates approximately 2.46M in revenue per employee across its workforce of 138.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Ironwood Pharmaceuticals, Inc. Class A recorded 67.84M in income tax expense. That works out to an effective tax rate of 37.38, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 181.52M, leaving 113.67M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Ironwood Pharmaceuticals, Inc. Class A's stock has gained approximately 137.59% over the past 52 weeks. The 50-day moving average sits at 3.55, while the 200-day moving average is 3.47.

Over the twelve months ended June 30, 2026, Ironwood Pharmaceuticals, Inc. Class A generated 340.77M in revenue and converted that into 113.67M in net income, yielding earnings per share of 0.67. EBITDA reached 206.57M, while operating income came in at 206.64M.

As of June 30, 2026, Ironwood Pharmaceuticals, Inc. Class A holds 69.26M in cash and equivalents against 347.38M in total debt, resulting in a net debt position of 267.73M. Total book value stands at -141.66M, with working capital of 145.60M providing operational flexibility.

Ironwood Pharmaceuticals, Inc. Class A produced 162.42M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -875.30 in capital expenditures, free cash flow totaled 162.42M - equivalent to 1.00 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of 60.64 and net profit margin of 33.36 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 25.93, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 28.57, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Ironwood Pharmaceuticals, Inc. Class A shareholders.

As of June 30, 2026, Ironwood Pharmaceuticals, Inc. Class A has an Altman Z-Score of -2.05, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.